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In silico selection of an aptamer 
to estrogen receptor alpha using 
computational docking employing 
estrogen response elements as 
aptamer-alike molecules
Rajesh Ahirwar1,2, Smita Nahar1,2, Shikha Aggarwal2, Srinivasan Ramachandran1,2, 
Souvik Maiti1,2 & Pradip Nahar1,2
Aptamers, the chemical-antibody substitute to conventional antibodies, are primarily discovered 
through SELEX technology involving multi-round selections and enrichment. Circumventing 
conventional methodology, here we report an in silico selection of aptamers to estrogen receptor alpha 
(ERα) using RNA analogs of human estrogen response elements (EREs). The inverted repeat nature 
of ERE and the ability to form stable hairpins were used as criteria to obtain aptamer-alike sequences. 
Near-native RNA analogs of selected single stranded EREs were modelled and their likelihood to 
emerge as ERα aptamer was examined using AutoDock Vina, HADDOCK and PatchDock docking. 
These in silico predictions were validated by measuring the thermodynamic parameters of ERα -RNA 
interactions using isothermal titration calorimetry. Based on the in silico and in vitro results, we 
selected a candidate RNA (ERaptR4; 5′-GGGGUCAAGGUGACCCC-3′) having a binding constant (Ka) 
of 1.02 ± 0.1 × 108 M−1 as an ERα-aptamer. Target-specificity of the selected ERaptR4 aptamer was 
confirmed through cytochemistry and solid-phase immunoassays. Furthermore, stability analyses 
identified ERaptR4 resistant to serum and RNase A degradation in presence of ERα. Taken together, an 
efficient ERα-RNA aptamer is identified using a non-SELEX procedure of aptamer selection. The high-
affinity and specificity can be utilized in detection of ERα in breast cancer and related diseases.
Human estrogen receptor α (ERα ), a 66 kDa ligand- inducible transcription factor is a key mediator of 
17β -estradiol induced proliferation, differentiation and development of breast and uterine tissues. ERα is a 
crucial biomarker useful in breast cancer diagnosis and treatment1,2. Presence of ERα in almost two-thirds of 
tumours and their subsequent treatment towards regression with hormonal therapy has established ERα as a use-
ful target for clinical purposes3–6. Detection of the altered expression of ERα in breast cancer and related diseases 
is carried out using ERα antibodies. However, the antibody- based applications are usually fraught with high 
costs and complexity of production, batch to batch variability, cross-reactivity, contamination, and short shelf 
life7–9. The substitute to conventional antibodies could be met by next generation affinity molecules that overcome 
the limitations of cost, synthesis, stability and specificity of target-binding9. Aptamers have gained considerable 
importance as selective and affinity-binding molecules due to the fact that the need for animals is obviated in their 
production with the added advantage of reduced time and production cost. Aptamers are short oligonucleotides 
that can be raised against almost every molecule10,11. They offer great advantages due to their high target speci-
ficity, affinity, low molecular weights and the usual non-immunogenic nature12. Aptamers are mostly identified 
through an iterative process called systematic evolution of ligands by exponential enrichment (SELEX), which 
is a cyclic process that involves multiple rounds of selection and amplification11. The entire process is tedious, 
time consuming and often fails to enrich high affinity aptamers13. Additionally, the requirement of fixed priming 
sites in the sequences of a library imposes a length criterion on random region, thereby restrict the diversity of 
the synthesized aptamer library. Even the lengthy aptamers, usually ≥ 40 nt long require prior trimming and 
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shortening for their efficient scale-up production. Recently, ER targeting aptamers have been identified using 
classical SELEX screening employing multiple rounds of protein-aptamer binding, selection, amplification and 
enrichment14. However, these aptamers were too lengthy and required truncations to obtain smaller aptamers. In 
a similar approach, He X. et al., reported the use of conditioned library for a selection of the ER-aptamer, but they 
still required conventional SELEX for aptamer screening15. Bioinformatic approaches that can combine in vitro 
and in silico methodologies could provide better solutions for aptamer screening and selection16,17. Methodologies 
such as DNA/RNA microarray provide high throughput mean to isolate aptamers, but at the same time, are lim-
ited by the requirement of pre-selected pool of minimal sequence numbers (~104–105) for chip synthesis. Also, 
the method that relies on a specifically designed RNA pool for aptamer selection against specific-analytes can be 
restricted by requirement of heavy computation and time16.
To identify an ERα -targeting aptamer by a non-SELEX procedure, we hypothesize that the estrogen response 
elements, which are the stretches of B-DNA in the promoter region of the genes regulated by estrogen recep-
tors18,19, can be utilized to obtain a pool of aptamer-alike sequences for in silico screening. Their inverted repeat 
nature and potential to interact with ERα in vivo provides a way to mimic these characteristics in an in silico 
system. Virtually the single strands of the EREs having inverted repeats can adapt stable hairpins and may act as 
potential aptamers. To prove this, we have developed a non-SELEX method that combines the in vivo chemistry 
of ERE structure and interactions with computation modelling and molecular docking to identify an ERα bind-
ing aptamer. Accordingly, a selection criterion is drawn to obtain hairpin-forming EREs and their RNA analogs 
are modelled to analyze their binding with ERα using AutoDock Vina, HADDOCK and PatchDock docking20–22. 
These in silico predictions are further validated by in vitro affinity measurement. A candidate sequence is selected 
as ER-aptamer and evaluated for its target- specificity. Also, solid-phase assays are performed to demonstrate the 
antibody-alternative action of the selected ERα -aptamer.
Results
Structural and functional selection of EREs and their 3D structure modelling. ERs execute the 
expression of target genes either by binding directly to EREs or by associating and recruiting transcriptional 
machinery at the promoter sites of ER target genes23. Many genes in human have been identified to contain ERE 
in their promoter proximal regions, where the ER complex binds and initiates the transcription of target genes. 
We have used these specialized ERE-ER interactions as a model towards developing ERα binding RNA aptamers. 
The fact that the ERs interact directly to ERE have offered us to model sequences analogous to EREs. In addi-
tion, we aimed to preserve the inverted repeat structure of the modelled sequence similar to the natural EREs. 
Therefore, a selection criterion was drawn to select human EREs which are full length inverted repeats and also 
involve in direct binding with ER in vivo. The prerequisite of full-length palindromes was to ensure the selected 
sequences to adopt stable hairpin loops. At the same time, the requirement of in vivo interacting partners was 
made to capitalize the inherited binding inclination of ERs for EREs. As a result of the designed selection crite-
rion, we obtained eighteen EREs that matched our criteria (Table 1). These selected EREs are present mainly in 
the genes that code for catalytic proteins, the proteins of the immune system, hormones, growth factors, and pro-
teins that are involved in cancer initiation and progression. As listed in Table 1, we select the sense strands of these 
EREs and model their RNA analogs using MC-Fold and MC-Sym algorithms24. For the majority of the modelled 
RNAs, the average number of generated tertiary structures ranged between five to hundred. We observed that 
Target gene description Target ERE sequence Reference
Telomerase reverse transcriptase TTGGTCAGGCTGATCTC 40
Trefoil factor 1 (pS2) AAGGTCACGGTGGCCAC 41
Keratin-19 TAGGTCAGTAAGACCTC 42
Oxytocin GGGGTCAAGGTCACCGC 43
Hageman Factor XII TTGGTCAAGCTGCCCTC 44
Complement C3 AGGGTCAGGGCCACCTG 45
Lactotransferrin CAGGTCAAGGCGATCTT 46
Angiotensin CGGGTCACGATGCCCTA 47
Transforming growth factor, alpha† GCGGTCACCGTCACCTC 48,49
Transforming growth factor, alpha†† GGGGTCAGCTGTGCCCCG 48,49
Vascular endothelial growth factor CCAGTCAGTCTGATTAT 50
Lipocalin-2 GAGGTCACTGAGACCAT 51
Cathepsin D CCGGTCACGTGGGCGCG 52
Estrogen-Responsive Finger Protein AGGGTCATGGTGACCCT 53
Cytochrome c oxidase subunit VIIa related protein GGGGTCAAGGTGACCCC 54
Estrogen receptor binding site associated antigen 9 CGGGTCAGGGTGACCTC 54,55
Human genome Alu ERE CAGGTCAAGGCGATCTT 56
Solved crystal structure CAGGTCACAGTGACCTG 36
Table 1.  List of the target genes and corresponding single-stranded estrogen response element sequences 
used for RNA modeling and aptamer predictions. †Location of estrogen responsive region − 252 to − 200. 
††Location of estrogen responsive region − 1527 to − 1511.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:21285 | DOI: 10.1038/srep21285
the number of generated tertiary structures was more for sequences forming moderately stable hairpins, whereas 
these numbers remained confined to a few for sequences that form strong hairpins. We only selected structures 
having the lowest free energy (near native structure) for each of the modelled RNA. As depicted in Fig. 1, these 
modelled RNAs were used as ligand in the subsequent docking experiments.
Virtual screening to identify probable aptamers for ERα. To identify the ability of modelled RNA 
sequences to emerge as ERα aptamer, we designed an in silico approach that used these RNAs as ligand to pre-
dict their binding with ERα . For this binding prediction, we used three different docking platforms, namely the 
AutoDock Vina, HADDOCK and PatchDock.
The designed in silico approach was first tested on a set of putative aptamer-protein complexes to evaluate 
its target-specific predictions. Thrombin-RNA aptamer complex25 and VEGF165-RNA aptamer complex26 were 
selected as test complexes. PDB coordinates of thrombin (1PPB) and VEGF165 (2VGH), and modelled aptamers 
(Thrombin: 5′ -gggaacaaagcugaaguacuuaccc-3′ ; VEGF165: 5′ -ccgguagucgcauggcccaucgcgcccgg-3′ ) were used as 
input in AutoDock Vina, HADDOCK and PatchDock docking. In parallel, the efficacy of the in silico approach 
was tested by performing control docking using similar length random RNA sequences (Table S1). The obtained 
docking scores from all the three docking algorithms were normalized to an arbitrary unit using mean centered 
Z score as calculated using equation27:
=
( − )
( )Z
E E
SD 1
where E is the obtained binding score of individual RNA- protein complex (in a set of 10 best binding modes), Ē is 
the mean binding score and SD is the standard deviation. Most negative Z-score in a set of 10 best binding modes 
of an RNA-protein complex was taken as docking specific Z-score of that particular complex. Total Z-score 
(ZT) was computed by adding the Z-scores of HADDOCK (ZH), PatchDock (ZP) and AutoDock Vina (ZAV). We 
obtained a ZT value of − 5.6 and − 5.0 for thrombin-RNA aptamer complex and VEGF165-RNA aptamer com-
plex, respectively (Supplementary Table 1). Contrary to this, the ZT scores of random-RNAs complexed with the 
thrombin (mean = − 3.62, SD = − 0.29, t(5) = 8.97, p value = 0.0003) and VEGF165 (mean = − 3.40, SD = − 0.25, 
t(5) = 8.38, p value = 0.0004) were found to be significantly low. This suggests that the designed in silico approach 
of aptamer selection can selectively predict and differentiate among target-specific and non-specific binding part-
ners in a DNA-protein complex.
After the method testing, we predicted binding partners for ERα (1SJ0) using the selected RNA sequences as 
ligands. Eighteen docking experiments, using AutoDock Vina, HADDOCK and PatchDock docking algorithms 
were carried out to predict the most probable aptamer in the collected set of sequences. The strength of the 
binding interactions in resulting complexes was estimated using ZT scores (Table 2). Further, control docking 
were performed using hairpin-forming random RNA sequences to ascertain the specificity in the predictions 
(Supplementary Table 2). The variance in the ZT scores of ERα -RNAs (ERaptR1-ERaptR18) and ERα -random 
RNAs complexes were measured using t-test analysis. The results showed a statistically significant difference 
in the ZT values of random RNAs (mean = − 3.56, SD = 0.51, n = 5) and RNA analogs of ERE (mean = − 4.44, 
SD- = 0.76, n = 18, t(21) = 2.73, p value = 0.0273). Further, this difference in ZT score got more pronounced 
when we analyzed the predicted binding of random RNAs with only the top five candidates from the ZT sorted 
RNAs (mean = − 5.19, SD = 0.36, n = 5, t(8) = 5.75, p value = 0.0004 ). This suggested that not all RNA hairpins 
can form stable complexes with ER. Also, this indicates that the ERα -RNA complexes with highest ZT scores may 
better represent the near-native complexes, and emerge as promising aptamer to ERα . To test this assumption, 
we further analyzed the role of hydrogen bonds and hydrophobic interactions in these predicted aptamer-protein 
complexes28. We estimated the strength of binding in the selected ER-RNA complexes by measuring the inter-
molecular H-bonds and hydrophobic interactions (Fig. 2). Although, none of the predicted complexes showed 
Figure 1. Flow chart showing the designed in silico approach of non-SELEX selection of an ERα binding 
aptamer. 
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an overall advantage of hydrophobic interactions, the aptamer-protein complex of ERaptR4 (predicted by 
HADDOCK, PatchDock and AutoDock Vina) was found to form the maximum number of intermolecular 
H-bonds with the ER protein (Fig. 2). The detailed description of the predicted interacting (partner) atoms is 
provided in supporting information (Table S3).
Also, as the selected RNA sequences form stable hairpins, we assumed that the free energy of secondary struc-
ture formation might play some role in deciding the binding energetics of the ERα -RNA complex. Accordingly, 
we predicted the free energy (Δ G) of secondary structure formation for selected probable aptamers and compared 
them with the mean free energy of the control RNAs that form similar hairpin structures (Table 3). However, we 
found no significant difference in the predicted Δ G value of probable aptamers (M = − 6.96, SD = 2.61) and the 
random RNAs (M = − 3.68, SD = 2.78; t(8) = 1.92, p-value = 0.0911). This further supports our previous predic-
tion that irrespective of similar hairpin formation, the selected probable aptamers form an energetically stable 
complex with ERα .
Taken together, the in silico predictions (ZT score and H-bond interaction) suggests that the selected 
RNA analogs of the ERE can emerge as aptamers to the ERα . Moreover, the ZT sorted top five candidates 
(ERaptR1-ERaptR5) holds higher potential to act as prominent ERα -aptamer.
In silico predicted RNA candidates emerged as high affinity and specific aptamers to 
ERα. Evaluation of the in silico predictions was carried out by measuring the binding affinities of all the proba-
ble aptamers (RNAs) with ERα using isothermal titration calorimetry. A hairpin forming random RNA was used 
as a random control. As summarized in Table 4 (also Fig S1–S4), the majority of the selected RNAs showed a pref-
erential binding to the ER with the values of binding constant (Ka) of an order of 107 M−1. However, we obtained 
no detectable binding between selected random RNA sequence and the ERα. Interestingly, the thermodynamic 
parameters (Δ H and Δ G) of ERaptR4 binding to ER were found to be most favoured for its selection as an RNA 
aptamer to ERα (Fig. 3A and Table 4). Although the ERaptR17 also showed similar binding, we only tested the 
ERaptR4 as a candidate aptamer and performed investigations to analyze its specificity for ERα .
Nevertheless, we also performed aptamer-assisted ELISA29 to analyze the binding characteristics of selected 
sequences in solid-phase assays. The relative binding of the top five RNAs (ERaptR1-ERaptR5) with ERα was 
assessed with an ERα -antibody control. As depicted in Fig. 3B, the ERaptR4 showed a relatively better binding to 
ERα . These results were in agreement with the in silico predictions and thermodynamic measurements.
Altogether, the predicted ZT score, H-bond interactions, and the measured value (Ka) of ER-ERaptR4 binding 
confirm the likelihood of ERaptR4 as a promising aptamer to ERα . The observed differences in the predicted 
order (ZT-sorted) of aptamers and the calculated values of binding constants could be attributed to the mechanis-
tic differences in the in silico and in vitro systems. Nevertheless, the occurrence of an ERα aptamer in the  selected 
EREs provides a measure of the feasibility of the present method in identifying aptamers in a non-SELEX manner.
ERaptR4 binding to ERα is highly selective. As the specificity of aptamers is an important aspect of 
their biological action, we evaluated the target specificity of the ERaptR4 in various solid phase assays. Aptamer 
and antibody- ELISA was carried out for detection of ERα in different samples varying in the complexity and 
Probable 
aptamers
Sequences of RNA analogs of 
aptamer-alike EREs†
AutoDock Vina 
Z-score (ZAV)
Haddock 
Z-score (ZH)
PatchDock 
Z-score (ZP)
Total Z-score 
(ZT)
ERaptR1 GAGGUCACUGAGACCAU − 2.04 − 2.05 − 1.62 − 5.70
ERaptR2 CCAGGUCACAGUGACCUG − 1.56 − 1.89 − 1.87 − 5.32
ERaptR3 AGGGUCAGGGCCACCUG − 2.21 − 1.53 − 1.54 − 5.28
ERaptR4 GGGGUCAAGGUGACCCC − 1.76 − 1.87 − 1.27 − 4.90
ERaptR5 AAGGUCACGGUGGCCAC − 1.36 − 1.98 − 1.45 − 4.79
ERaptR6 UAGGUCAGUAAGACCUC − 1.89 − 2.31 − 0.57 − 4.77
ERaptR7 CGGGUCACGAUGCCCUA − 1.90 − 1.91 − 0.95 − 4.76
ERaptR8 CGGGUCAGGGUGACCUC − 1.78 − 1.99 − 0.98 − 4.75
ERaptR9 UGGUCAGGCUGGUCUCA − 1.31 − 1.38 − 1.95 − 4.63
ERaptR10 CCGGUCACGUGGGCGCG − 1.53 − 1.44 − 1.63 − 4.60
ERaptR11 AGGGUCAUGGUGACCCU − 0.99 − 1.74 − 1.87 − 4.59
ERaptR12 GGGGUCAAGGUCACCGC − 1.50 − 1.61 − 1.42 − 4.52
ERaptR13 CAGGUCAAGGCGAUCUU − 1.67 − 1.36 − 1.23 − 4.26
ERaptR14 CCAGUCAGUCUGAUUAU − 1.30 − 2.02 − 0.68 − 4.00
ERaptR15 GCGGUCACCGUCACCUC − 1.41 − 1.29 − 0.76 − 3.47
ERaptR16 UUGGUCAGGCUGAUCUC − 1.17 − 1.84 − 0.38 − 3.38
ERaptR17 UUGGUCAAGCUGCCCUC − 1.33 − 1.18 − 0.73 − 3.24
ERaptR18 GGGGUCAGCUGUGCCCCG − 1.12 − 1.27 − 0.51 − 2.89
Table 2.  Z-score values of docking predicted ERα-RNA complexes. Docking-specific Z-scores (ZAV, ZH, 
and ZP) for individual ERα -RNA complex was calculated using the individual binding score and mean binding 
scores in a set of 10 best binding modes of a sequence. Total Z-score (ZT) was taken as sum of individual 
docking-specific Z-scores. †The mentioned RNA sequences represent their respective complex with 1SJ0 (ERα ).
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availability of target-ERα . As depicted in Fig. 4A, the aptamer was found to produce an antibody-equivalent sig-
nal in almost all the analyzed samples. The aptamer showed no binding with the cellular extracts of ERα -deficient 
MDA MB-231 cells, but produced an excellent signal in the nuclear and cytoplasmic extracts of ERα -positive 
MCF-7 cells. This shows that the aptamer can specifically target the ERα without any cross-reactivity to 
non-target components.
These observations were further confirmed through ERaptR4-assisted western blot assay, wherein the SDS 
PAGE separated samples of ERα were detected using biotinylated ERaptR4 instead of an ERα -antibody. As 
shown in Fig. 4B, the presence discrete bands at 66 kDa (full length ERα ) and 46 kDa (transcript variant) in puri-
fied -ERα and MCF-7 nuclear extract samples support the specific binding of ERaptR4 to ERα . Absence of such 
discrete bands in the extracts of MDA MB-231 breast cancer cells suggests the lack of cross-reactivity. Further, 
we checked the cross reactivity of ERaptR4 against the progesterone receptor. As shown in Fig. 4C, we found an 
insignificant binding of ERaptR4 to the DNA binding and ligand binding domains of PR. Despite of considerable 
Figure 2. Analysis of the predicted intermolecular interactions in the selected ERα-RNA complex. (A,B) 
Numbers of the predicted hydrophobic interactions and H-bonds in complex of ERα with ERaptR1-ERaptR5. 
These interactions are predicted using Ligplot and Nucplot. (C) Ribbon view of the HADDOCK predicted 
ERα (1SJ0)-ERaptR4 complex, depicting the interacting residues and the spatial arrangement of protein 
chains in the vicinity of aptamer molecule. (D) H-bonding residues in the AutoDock Vina generated complex 
of ERα -ERaptR4. The blue colour represents the aptamer bases while the green colour indicates the amino 
acids. (E) Surface view of the PatchDock generated ERα -ERaptR4 complex showing the relative orientations of 
interacting bases and amino acid chain. (F) Structural representation of H-bond and hydrophobic interactions 
in the ERα -ERaptR4 complex as predicted using Ligplot. H-bonds are represented by dashed lines between 
H-bonding atoms, whereas the hydrophobic interactions are shown by an arc with spokes radiating towards the 
interacting ligand atoms.
S. No. Sequence
Sequence 
name
Length 
(nt)
Predicted ΔG 
(kcal/mol)
1 gaggucacugagaccau ERaptR1 17 − 5.70
2 ccaggucacagugaccug ERaptR2 18 − 8.60
3 agggucagggccaccug ERaptR3 17 − 4.40
4 ggggucaaggugacccc ERaptR4 17 − 10.70
5 aaggucacgguggccac ERaptR5 17 − 5.40
6 uagcuuaucagacug Random1 15 − 0.21
7 gcugggaaacacccagg Random2 17 − 7.80
8 guugcauuuaggugcau Random3 17 − 4.30
9 cauagcagacagcuauc Random4 17 − 3.70
10 aauuuccacaggaaagca Random5 18 − 2.40
Table 3.  Predicted free energy of secondary structure formation of probable RNA aptamers and random 
RNA sequences.
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RNA 
sequences n Ka (M−1) ΔH (kcal/mol) TΔS (kcal/mol) ΔG (kcal/mol)
ERaptR1 0.4 9.20E + 07 − 109.6 − 98.6 − 10.96
ERaptR2 0.5 7.60E + 07 − 103.6 − 92.6 − 10.92
ERaptR3 0.4 5.24E + 07 119.3 − 108.7 − 10.53
ERaptR4 0.5 1.02E + 08 − 100.2 − 89.1 − 11.10
ERaptR5 0.4 6.82E + 07 − 97.2 − 86.4 − 10.78
ERaptR6 0.4 9.46E + 07 − 89.5 − 78.6 − 10.82
ERaptR7 0.5 4.82E + 07 − 84.8 − 74.2 − 10.60
ERaptR8 0.5 8.88E + 07 − 117.8 − 106.9 − 10.81
ERaptR9 0.5 9.46E + 07 − 97.2 − 86.4 − 10.78
ERaptR11 0.5 8.02E + 07 − 104.7 − 93.8 − 10.83
ERaptR12 0.4 8.20E + 07 − 100.5 − 86.8 − 10.80
ERaptR13 0.4 8.96E + 07 − 89.7 − 78.9 10.73
ERaptR14 0.3 7.42E + 07 − 100.6 − 89.6 − 10.90
ERaptR15 0.3 9.25E + 07 − 140.3 − 129.3 − 10.96
ERaptR16 0.4 9.40E + 07 − 124.7 − 113.8 − 10.86
ERaptR17 0.4 1.26E + 08 − 99.5 − 88.5 − 10.99
ERaptR18 0.3 9.91E + 07 − 108.3 − 97.7 − 10.55
Table 4.  Thermodynamic parameters derived from ITC for ER-RNA (ERE analogs) interactions at 
25 °Ca,b. aAll parameters (n = number of binding sites, Ka = association constant, Δ H = change in enthalpy, 
TΔ S = change in entropy, Δ G = Gibb’s free energy) were derived from ITC experiments conducted at 25 °C in 
Tris-HCl buffer (pH 8.0). Protein (ERα ) concentration in cell was taken as 1 μ M and RNA aptamers (R1 − R18) 
in syringe were taken as 10 μ M. Δ H, Δ S, Δ G values are within 5% error and Ka values are within 10% error 
obtained from the three experimental replicates. bBinding parameters for aptamer ERα -ERaptR10 couldn’t be 
calculated due to some unexpected irregularity in the synthesis of ERaptR10.
Figure 3. Measuring the in vitro affinities of the in silico selected ERα-aptamers. (A) ITC isotherms of 
ERα interactions with aptamer ERaptR4. For each titration, the ERα concentration in 1.4 ml sample cell was 
taken as 1 μ M and aptamer concentration in syringe was 10 μ M. The top panel represents the raw heats of 
binding obtained upon titration of aptamer to ERα protein. The lower panel is the binding isotherm fitted to 
the raw data using one site model. (B) ELISA-based measurement of the relative binding of selected sequences 
with ERα . Binding of aptamer candidates is presented after normalizing against the ERα -antibody control. A 
random 17-mer RNA sequence (5′ -aucgugugcugcuacga-3′ ) is taken as a random RNA control.
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homology in the ER and PR, the lack of ER aptamer-binding to PR suggests the high target specificity of the in 
silico selected aptamer.
Further validation of the affinity and specificity of ERaptR4 for ERα was carried out using chromogenic cyto-
chemistry performed on MCF-7 and MDA MB-231 breast cancer cells. The formalin-fixed monolayer culture 
of these cells were stained with biotinylated ERaptR4 and visualized under microscope. As depicted in Fig. 4D, 
the ERaptR4 bind selectively to the ERα present in the nuclear region of MCF-7 cells, without cross reacting to 
other cellular/extracellular components. Also, the ERaptR4 showed no binding to any of the cellular components 
of ERα -deficient MDA MB-231 cells. Furthermore, these observations suggest the diagnostic applicability of 
ERaptR4 in detecting the ERα in breast cancer or related diseases.
ERaptR4 can sustain nuclease and serum degradation in presence of ERα. Shelf life and nuclease 
stability are two important parameters that can decide the clinical and research utility of an aptamer. Towards this, 
we have analyzed the stability of ERaptR4 against the RNase and serum degradation. The target-dependent stabil-
ity of aptamer against RNase A was tested using the classical RNA protection assay. As shown in Fig. 5A, ERaptR4 
showed complete rescue from nuclease digestion in the presence of its target protein. However, in absence of 
ERα , the aptamer is susceptible to nuclease degradation. Thus, the diagnostic assays that will involve the ERα 
would be least hindered by the problem of nuclease digestion, as the ER will act as a mask to the aptamer. Also, we 
measured the stability of ERaptR4 aptamer in 10% foetal bovine and human (female) serum. We observed that 
ERaptR4 undergoes a time dependent degradation in both the serum samples; the rate of aptamer degradation 
was faster in foetal bovine serum with an approx. half life of 100 minutes. However, the same aptamer has resisted 
the degradation in human serum as indicated by the approx. half life of 240 minutesFig. 5B. The conditions of 
Figure 4. Validating the target specificity of ERaptR4 aptamer. (A) The specificity of ERaptR4 binding to 
ERα , as estimated by an ELISA-based detection of purified ERα , nuclear and cytoplasmic extracts of MCF-7 
and MDA MB-231 cells and human serum proteins, using biotinylated ERaptR4 as detection molecule. A 17-
mer random RNA sequence (5′ -aucgugugcugcuacga-3′ ) was used as random RNA control. Data is plotted 
after subtracting the background binding. (B) Western blot analysis of SDS PAGE separated ERα , MCF-7 and 
MDA MB-231 nuclear extract using biotinylated ERaptR4. (C) ELISA-detection of ER (lbd) and PR (lbd and 
dbd) using biotinylated ERaptR4. Random RNA and ER-antibody were taken as negative and positive controls, 
respectively. (D) Cytochemical detection of ERα in the fixed monolayer culture of MCF-7 and MDA MB-231 
breast cancer cells as carried out using biotinylated-ERaptR4.
www.nature.com/scientificreports/
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the hosts during the time of serum isolation and the difference in their nucleases profile could have accounted 
for such observations. However, for the majority of the detection assays, a serum half life of 100 min can yield 
sufficient results without compromising the specificity or affinity of the method.
Discussion
Selection of aptamers using the classical Systematic Evolution of Ligands by Exponential Enrichment (SELEX) 
method has some inevitable shortcomings that limit its efficacy to produce high affinity and selective-aptamers 
in a reasonable time and with limited resources. The SELEX process needs repetitive selection and enrichment, 
optimally 10–20 to enrich an aptamer. This makes the selection process to last for weeks to months. Similarly, the 
use of priming regions in the sequences of an aptamer library can hinder the aptamer-target interactions. This can 
even result in enrichment of low affinity binders. Also, the constant regions at the end of each sequence restrict 
the diversity of synthesized libraries or requires synthesis of longer libraries to achieve an adequately diverse pool. 
As an alternate, methodologies such as microarray, high throughput sequencing or computation-assisted SELEX 
have been reported to ease the process of aptamer selection. However, the requirement of the lesser population 
of sequences (e.g. 104-105) for microarray and the heavy computations in reported in silico methods limit the 
effective utilization of the alternate methods30–33.
The present study overcomes some of these limitations by reporting a non-SELEX method of ERα -aptamer 
selection. We applied the novel concept of using selective single stranded EREs as a probable pool of ERα -specific 
aptamers. Though the in vivo binding of dimerized estrogen receptors at double stranded ERE of target genes have 
been known for decades and many studies have reported these interactions in an in vitro system as well18, there is 
hardly any report on the binding of a single stranded ERE to a monomeric ER. In the single strand conformation, 
these EREs can adopt stable hairpins because of their inverted repeat nature. Further, they retain their inherent 
binding for ER as we selected only full length EREs. On the basis of these, we reasoned that hairpin forming 
full-length EREs can mimic structures akin to the aptamers. As the number of known EREs is vast, this required 
a selection procedure to obtain such aptamer-alike sequence. We capitalized the aptamer-likeness of EREs by 
selecting full length palindromic EREs that can form stable hairpins. Interestingly, as the criterion of ERE selec-
tion is dependent on their structural makeup, a similar approach can also be utilized to obtain hormone response 
elements as probable aptamer pool for other nuclear receptors. This also makes our approach a method of choice 
for non-SELEX selection of aptamer for various nuclear receptor transcription factors.
Further, as RNA aptamers are known to possess higher structural and functional adaptability and prove more 
pivotal than DNA aptamers34,35, we converted the selected single strands of EREs from their DNA to RNA ana-
logs to avail the RNA-associated benefits. These RNAs were used as ligand in a docking approach that used three 
docking algorithms to capture a wide spectrum of docking predictions. AutoDock Vina is a flexible docking 
algorithm that uses Monte Carlo simulated dockings to predict the native binding mode of protein-RNA com-
plex. HADDOCK (High Ambiguity Driven DOCKing) is a data driven method that predicts minimal energy 
conformations from experimentally or bioinformatically available interaction information. Unlike the two, the 
PatchDock is a geometry-based rigid-body docking that provides complexes which are sorted by molecular 
shape complementarity criteria. The approach of using three docking algorithms to predict the binding of an 
RNA-protein complex was tested on pre-defined molecules and found to selectively differentiate in to specific 
and non-specific binding partners of a protein. Using this approach, we have shown that hairpins forming EREs 
can be raised as ERα aptamer. Concomitant statistical analyses were done to prove the significance of the in silico 
predictions.
We further validated these in silico predictions by measuring the in vitro affinity and specificity of selected 
sequences. With the help of isothermal titration calorimetry, we have shown that the RNA analogs of ERE that 
we initially obtained as a pool of probable ERα -aptamers are indeed the true binding partners of ERα . All the 
Figure 5. Stability analysis of ERaptR4. (A) Nuclease stability of ERaptR4, as measured using the RNA 
protection assay. ERaptR4 (2.0 μ g) was incubated with RNase A in the presence of 0.5, 1.5 and 3.0 μ g of 
ERα . The samples were separated on 2.0%. The un-degraded ERaptR4 was detected using EtBr staining. (B) 
Serum stability of ERaptR4 was examined in 10% foetal calf serum and human serum for time intervals of 
0–1200 minutes. The un-degraded ERaptR4 was determined by separating it on 2% agarose and EtBr staining. 
The graph was normalized by taking the fluorescence intensity of initial sample (0 min) as 100%.
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selected RNAs showed a preferential and high affinity binding for ERα . The lack of binding between ERα and a 
random RNA (hairpin) provided the measure of the target specificity of selected probable aptamers. Further, a 
stoichiometry of 0.5 for RNA-ERα binding is indicative of the presence of two binding sites (corresponding to 
each half ERE) on selected RNAs analogs of the EREs. Nevertheless, the docking -predictions has made it easy to 
shortlist the most prominent aptamer among selected RNAs. The in silico anticipation of the maximum hydro-
gen bonds and the favouring thermodynamics of the ERα -ERaptR4 interaction at 25 °C (Δ G = − 11.1 kcal/mol; 
Ka = 1.02 ± 0.1 × 108 M−1) are the indicative of high affinity and selective binding of ERaptR4 to ERα .
As the conventional method of ER detection mostly uses antibodies; by substituting the ER-antibody by 
ERaptR4 in assays such as the aptamer-assisted ELISA, western blot, and cell-imaging, we have shown that the 
ERaptR4 can efficiently alternate the ERα -antibodies in these immunoassays. These successful attempts to specif-
ically detect and quantify ERα in solid- or solution-phase assays provided additional evidence on target- specific-
ity of the selected ERα aptamer. Further, as the proteins of the nuclear receptor family share conserved domains 
among various receptors, we checked the cross reactivity of ER-aptamer with the progesterone receptor. The lack 
of binding to either the LBD or DBD of PR promises high target specificity and concomitant applicability of the 
ERaptR4.
In conclusion, our study provides an RNA aptamer to ERα , selected through a non-SELEX in silico method 
of aptamer selection. The single stranded estrogen response elements were used as a pool of probable aptam-
ers and their aptamer-likeness was predicted using computational dockings. As the developed in silico method 
SELEX-free aptamer selection is cost effective, simple and does not require sophisticated instruments, it can be 
applied to obtain aptamer against other nuclear receptors.
Methods
Selection of ERE sequences and their tertiary structure predictions. Putative EREs were screened 
according to the designed criteria. EREs with extended half-site were removed and not included in the selec-
tion. Sense strands of selected 17 EREs that matched our criteria and a sequence form solved crystal structure 
of ERα -DNA complex36 were chosen for tertiary structure modelling using MC-Fold and MC-Sym algorithm 
(http://www.major.iric.ca) to obtain tertiary RNA analogs of selected EREs. MC-Fold MC-Sym algorithms work 
in a pipeline mode, where the MC-Fold generate secondary structures for each input RNA sequence and these 
structures are used as input sequences by MC-Sym to model all possible tertiary structures. Minimum free energy 
structures corresponding to each input sequence were selected and used as ligands in subsequent in silico docking 
analysis.
Virtual screenings. The PDB coordinates of ER LBD (1SJ0, resolution 2.03 Å) were taken from Protein Data 
Bank and prepared for dockings by deleting undesired protein chains and ligand. For AutoDock Vina, the grid 
box was specified in the coordinate system of ER corresponding to BindN+ 37 predicted RNA-binding amino 
acids. Grid box was created with a default value of 0.375 Å for spacing between the grid points centering at 
11.139, 10.861, 9.611 and 60, 62, 68 points in x, y and z dimensions, respectively. Docking was carried out at HPC 
environment. Vina generates a single pdbqt file containing top ranked binding modes of minimum free energy 
conformation upon successful completion of docking. HADDOCK dockings were performed on easy interface 
of the server using already prepared receptor and ligand files. HADDOCK uses ambiguous interaction restraints 
to run the docking process repetitively, to insure generation of the highest number of correct decoys. Further, 
any decoys which are driven by wrong restraints were discriminated based on their lower scores compared to the 
correct decoys. Output decoys are provided as water-refined structure sorted by its HADDOCK-score. Molecular 
shape complementarity docking was performed over PatchDock web server. Prepared PDB files of ligand and 
receptor was provided to PatchDock server at default value of 4.0 for clustering RMSD and default complex type. 
PatchDock represents the Connolly’s surface of docking partners as concave, convex and flat patches and matches 
them to generate candidate transformations. The PatchDock-generated transformations (protein-RNA complex) 
were further refined by FireDock38 to obtain best transformations from each dockings. In total, 18 independent 
docking runs were performed with each docking algorithm to evaluate the ERα binding potential of individual 
RNA analog.
Isothermal titration calorimetry. Dissociation constant was measured using isothermal titration calo-
rimetry experiment performed at 25 °C using a MicroCal VP-ITC (MicroCal, Inc., Northampton, MA, USA). 
ERα and aptamer solutions were prepared in 10 mM Tris-HCl, pH 8.0. The thermal equilibration step at 25 °C 
was followed by an initial 120 s delay step and the subsequent twenty five injections of 10 μ M ERaptR4,injected 
at 370 rpm to 1.0 μ M of ERα protein (injection duration of 10 s and spacing of 180 s). Each injection generated a 
heat-burst curve between micro cal s− 1 versus time (min). The saturation curve between kcal/mol of injectant 
vs. molar ratio was determined by integration, using Origin 7.0 software (Microcal, Inc.) to give the measure of 
the heat associated with the injection. The resulting experimental binding isotherm was corrected for the effect 
of titrating estrogen receptor alpha to its binding buffer. The binding affinity and thermodynamic parameters of 
the binding process were obtained by fitting the integrated heats of binding the isotherm to the one site binding 
model to give a association constant (Ka), stoichiometry (n) and the binding enthalpy and entropy (Δ H, Δ S). The 
Gibbs free energy (∆G) was calculated using the equation39:
∆ = ∆ − ∆ ( )G H T S 2
Aptamer-assisted ELISA. Aptamer-assisted ELISA was carried out in FNAB activated microtiter plates car-
rying equivalent amount of immobilized ERα , the nuclear and cytoplasmic extracts of MCF-7 and MDA MB-231 
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breast cancer cells, and human serum proteins. The wells were loaded with 100 nM biotinylated ERaptR4, incu-
bated for 2 h and followed by detection of target bound aptamer using streptavidin-HPR conjugate. Specificity 
was estimated using the measured absorbance values against individual targets. In parallel, ERα antibody and a 
17-mer random RNA sequence was used as positive and negative controls, respectively.
Aptamer-assisted Western blot. Target samples were separated on 12% SDS PAGE and electroblotted to 
PVDF membrane. The membrane was then coated with 5% BSA, and afterwards incubated with 1 μ M ERaptR4. 
Development of the blot was carried out using streptavidin-HRP conjugate.
Aptamer-assisted cytochemistry assay. Cytochemistry assay was performed on p-formaldehyde fixed 
monolayer cultures of MCF-7 and MDA MB-231 cells. The fixed cells were permeabilized by 0.1% Triton X-100 
(in PBS) by 10 min incubation at RT. Cells were blocked with 1% BSA and 22.5 mg/ml glycine for 30 min and 
afterward incubated with 200 nM of biotinylated ERaptR4 for additional 2 hours. This followed PBS wash and 
subsequent incubation with streptavidin-HRP conjugate (1:500 dilution) at RT for 1 hour. Cover slip coated cells 
were then stained with DAB staining solution (500 μ L 1% DAB in 5 mL 1X PBS, 15 μ L H2O2) and counterstained 
with haematoxylin. After mounting with anti-fade mounting solution, the images of stained cells were taken 
using Nikon Eclipse i9 microscope.
Serum stability measurement. Serum stability of ERaptR4 was examined in 10% FBS and 10% human 
female serum. For this, 2 μ g of ERaptR4 in 10 μ L of respective serums was incubated for 0–20 h. Samples were 
collected at stipulated time periods and frozen immediately to − 70 °C until analyzed on 2% agarose gels.
RNase A digestion assay. RNase A digestion assay was performed by incubating 0.5 μ g, 1.5 μ g and 3.0 μ g of 
ERα with 10 μ M of ERaptR4. The binding was allowed for 30 min and then incubated with 100 μ g/mL of RNase 
A at 37 °C for 5 minutes. The reaction was terminated by heating the sample at 85 °C for 10 min, followed by treat-
ment with proteinase K (20 mg). The sample was then loaded on a 2% agarose gel in 1X TAE and run at 60V for 
30 min and visualized by EtBr staining.
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